- Home
- MP vs MRUS Comparison
MP vs MRUS Comparison
Compare MP & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MP
- MRUS
- Stock Information
- Founded
- MP 2017
- MRUS 2003
- Country
- MP United States
- MRUS Netherlands
- Employees
- MP N/A
- MRUS N/A
- Industry
- MP Metal Mining
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- MP Basic Materials
- MRUS Health Care
- Exchange
- MP Nasdaq
- MRUS Nasdaq
- Market Cap
- MP 4.0B
- MRUS 4.1B
- IPO Year
- MP N/A
- MRUS 2016
- Fundamental
- Price
- MP $37.70
- MRUS $53.11
- Analyst Decision
- MP Buy
- MRUS Strong Buy
- Analyst Count
- MP 9
- MRUS 12
- Target Price
- MP $27.06
- MRUS $87.92
- AVG Volume (30 Days)
- MP 13.0M
- MRUS 2.0M
- Earning Date
- MP 07-31-2025
- MRUS 07-31-2025
- Dividend Yield
- MP N/A
- MRUS N/A
- EPS Growth
- MP N/A
- MRUS N/A
- EPS
- MP N/A
- MRUS N/A
- Revenue
- MP $215,981,000.00
- MRUS $54,732,000.00
- Revenue This Year
- MP $23.82
- MRUS $75.57
- Revenue Next Year
- MP $88.68
- MRUS $31.84
- P/E Ratio
- MP N/A
- MRUS N/A
- Revenue Growth
- MP 4.63
- MRUS 42.77
- 52 Week Low
- MP $10.02
- MRUS $33.19
- 52 Week High
- MP $39.10
- MRUS $62.98
- Technical
- Relative Strength Index (RSI)
- MP 79.51
- MRUS 53.18
- Support Level
- MP $23.26
- MRUS $52.41
- Resistance Level
- MP $39.10
- MRUS $54.59
- Average True Range (ATR)
- MP 2.74
- MRUS 2.15
- MACD
- MP 1.54
- MRUS -0.77
- Stochastic Oscillator
- MP 92.63
- MRUS 7.62
About MP MP Materials Corp.
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.